NRX Pharmaceuticals (NRXP) Net Cash Flow (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Net Cash Flow data on file, last reported at -$1.1 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 126.53% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 11.73% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, up 301.97% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$1.1 million, down from $625000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for NRXP reached as high as $12.6 million in Q1 2022 and fell as low as -$15.7 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$1.1 million across 5 years, with a median of -$1.1 million in 2026.
• Across the five-year window, Net Cash Flow slumped 13712.17% in 2022 and soared 2812.3% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $1.8 million in 2022, then slumped by 338.61% to -$4.3 million in 2023, then surged by 95.29% to -$203000.0 in 2024, then surged by 407.88% to $625000.0 in 2025, then slumped by 274.24% to -$1.1 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$1.1 million in Q1 2026, $625000.0 in Q4 2025, and $6.8 million in Q3 2025.